Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with related health conditions. While primarily associated with gastrointestinal side effects, some patients report emotional changes including mood swings, tearfulness, or low mood whilst taking this medication. Understanding the potential link between Wegovy and emotional wellbeing is important for patients and healthcare professionals. This article examines current evidence, explores possible mechanisms, and provides guidance on managing emotional effects and when to seek medical advice during Wegovy treatment.

Understanding Wegovy and Its Effects on the Body

Wegovy (semaglutide 2.4mg) is a prescription medication licensed in the UK for weight management in adults with obesity (BMI ≥30kg/m²) or those who are overweight (BMI ≥27kg/m²) with weight-related health conditions such as pre-diabetes, type 2 diabetes, hypertension, or dyslipidaemia. It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes management but now used for chronic weight management following NICE guidance and MHRA approval.

The medication works by mimicking a naturally occurring hormone called GLP-1, which is produced in the intestines after eating. Semaglutide binds to GLP-1 receptors throughout the body, triggering several physiological responses that support weight loss. In the pancreas, it stimulates insulin secretion when blood glucose levels are elevated, helping to regulate blood sugar. In the stomach, it slows gastric emptying, which prolongs the feeling of fullness after meals. Most significantly for weight management, semaglutide acts on receptors in the brain's appetite centres, particularly in the hypothalamus, reducing hunger signals and food cravings.

Wegovy is administered as a once-weekly subcutaneous injection, typically starting at a low dose of 0.25mg and gradually increasing over 16 weeks to the maintenance dose of 2.4mg, with each dose level maintained for 4 weeks. This titration schedule helps minimise gastrointestinal side effects, which are the most commonly reported adverse reactions. If side effects are troublesome, the dose escalation can be delayed or the dose temporarily reduced to improve tolerability, as outlined in the UK SmPC. In the NHS, Wegovy is typically prescribed within specialist weight management services for up to 2 years, alongside lifestyle modifications including reduced-calorie diet and increased physical activity. Clinical trials have demonstrated that Wegovy can lead to significant and sustained weight loss. However, as with any medication that affects brain chemistry and metabolic processes, questions have been raised about potential effects on mood and emotional wellbeing.

Can Wegovy Cause Emotional or Mood Changes?

The relationship between Wegovy and emotional changes is an area of ongoing clinical scrutiny and regulatory review. During the initial clinical trials for semaglutide at the 2.4mg dose used in Wegovy, mood disorders were not identified as a prominent adverse effect in the primary safety data. The most frequently reported side effects were gastrointestinal in nature, including nausea, diarrhoea, vomiting, and constipation. However, post-marketing surveillance and real-world patient experiences have prompted further investigation into potential psychological effects.

Some patients taking Wegovy have reported experiencing emotional changes, including increased tearfulness, mood swings, irritability, or feelings of low mood. These reports have been sufficiently concerning that regulatory bodies, including the European Medicines Agency (EMA) and the MHRA, have conducted safety reviews of GLP-1 receptor agonists to assess whether there is a causal link between these medications and suicidal thoughts or self-harm. As of current guidance (2024), the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has stated that available evidence does not confirm a direct causal association between GLP-1 receptor agonists and suicidal ideation or behaviour, though monitoring continues.

It is important to recognise that establishing causality in such cases is complex. Many individuals seeking treatment with Wegovy may already have underlying mental health conditions, as obesity itself is associated with higher rates of depression and anxiety. The process of significant weight loss, regardless of the method, can also trigger emotional responses as individuals adjust to changes in body image, social interactions, and lifestyle. Furthermore, the physical side effects of Wegovy, particularly persistent nausea or fatigue, may indirectly affect mood and emotional resilience.

The UK SmPC for Wegovy advises healthcare professionals to monitor patients for depression or suicidal thoughts and to consider discontinuing treatment if these occur. If you experience mood changes while taking Wegovy, you should discuss these with your healthcare provider and consider reporting them through the MHRA Yellow Card scheme, which helps monitor medication safety.

Why GLP-1 Medications May Affect Mental Wellbeing

Several hypotheses have been proposed to explain why GLP-1 receptor agonists like Wegovy might influence emotional states in some individuals. One consideration is the distribution of GLP-1 receptors throughout the central nervous system. These receptors are not confined to areas controlling appetite and metabolism; they are also found in brain regions involved in mood regulation, reward processing, and emotional responses, including the hippocampus, amygdala, and prefrontal cortex. This anatomical distribution suggests that medications targeting these receptors could potentially influence emotional processing and psychological wellbeing, though the clinical significance remains under investigation.

Some research suggests that the mechanism by which semaglutide reduces appetite may involve interactions with dopamine pathways in the brain's reward system. Dopamine is a neurotransmitter critically involved in motivation, pleasure, and mood regulation. By potentially altering how the brain responds to food-related rewards, it is hypothesised that GLP-1 medications might affect other reward-processing systems. Some researchers have suggested that in susceptible individuals, this could theoretically contribute to changes in emotional responses or reduced pleasure in activities previously found enjoyable, though this remains speculative and requires further clinical research to establish.

Additionally, the metabolic changes accompanying significant weight loss can affect hormone levels and neurotransmitter balance. Adipose tissue is metabolically active and produces hormones such as leptin, which communicates with the brain about energy stores and can influence mood. Rapid changes in body composition may temporarily disrupt these signalling pathways. Furthermore, caloric restriction and dietary changes undertaken alongside Wegovy treatment can affect blood sugar stability, and fluctuations in glucose levels are known to influence mood, energy, and emotional regulation. Nutritional adequacy during weight loss is important, as deficiencies in key nutrients could potentially contribute to mood disturbances, highlighting the importance of maintaining balanced nutrition throughout treatment.

Managing Emotional Side Effects While Taking Wegovy

If you experience emotional changes whilst taking Wegovy, several strategies can help manage these effects whilst continuing to benefit from the medication's weight management properties. Firstly, maintaining open communication with your prescribing healthcare professional is essential. They can assess whether the emotional changes are likely related to the medication, underlying mental health conditions, or the psychological adjustment to weight loss, and can adjust your treatment plan accordingly.

Keeping a symptom diary can be particularly valuable, noting when emotional changes occur in relation to your injection schedule, dietary patterns, and life events. This information helps identify patterns and potential triggers. If mood changes coincide with dose increases, your healthcare provider may consider slowing the titration schedule, temporarily maintaining a lower dose, or even reducing to a 1.7mg dose to allow your body more time to adjust, as outlined in the UK SmPC. In some cases, the emotional effects may diminish as your body adapts to the medication over several weeks.

Ensuring adequate nutritional intake is crucial, as deficiencies in key nutrients such as vitamin B12, vitamin D, omega-3 fatty acids, and iron can contribute to mood disturbances. Working with a registered dietitian (available through NHS referral from your GP or weight management service) can help ensure you meet nutritional requirements despite reduced appetite and caloric intake. Regular physical activity, which is recommended as part of comprehensive weight management, has well-established benefits for mental health and can help stabilise mood. Even moderate activities such as walking, swimming, or yoga can provide psychological benefits alongside physical ones.

Psychological support should be considered an integral component of weight management treatment. Cognitive behavioural therapy (CBT) or counselling can help address emotional responses to body image changes, develop coping strategies for mood fluctuations, and manage any underlying mental health conditions. NHS Talking Therapies (formerly IAPT) services are available through GP referral or self-referral in many areas. Some NHS weight management services include psychological support as standard. Peer support groups, either in person or online, can also provide valuable emotional support from others undergoing similar experiences with weight management medications.

If you believe your emotional changes are medication-related, consider reporting them through the MHRA Yellow Card scheme, which helps monitor medication safety.

When to Seek Medical Advice About Mood Changes

Whilst mild emotional fluctuations may be manageable with self-care strategies, certain mood changes warrant prompt medical attention. You should contact your GP or prescribing healthcare professional if you experience persistent low mood lasting more than two weeks, particularly if this is accompanied by loss of interest in activities you normally enjoy, changes in sleep patterns, or feelings of hopelessness. These symptoms may indicate depression requiring specific treatment, which should not be dismissed as merely a side effect of medication.

Any thoughts of self-harm or suicide require immediate medical attention. Contact your GP urgently, call NHS 111, or attend your local accident and emergency department. If you are in immediate danger, call 999. The Samaritans are available 24 hours a day on 116 123 for confidential emotional support. NHS urgent mental health helplines are also available in all areas of England and can be found on the NHS website. Whilst current evidence does not establish a definitive link between Wegovy and suicidal ideation, any such thoughts must be taken seriously and assessed promptly by healthcare professionals who can provide appropriate support and determine whether continuing the medication is advisable.

Significant anxiety, panic attacks, or severe mood swings that interfere with daily functioning also warrant medical review. Your healthcare provider can assess whether these symptoms are related to Wegovy, require adjustment of your treatment plan, or indicate a separate condition requiring intervention. If you have a pre-existing mental health condition, any worsening of symptoms should be discussed with both your GP and any mental health specialists involved in your care, as medication adjustments or additional support may be needed.

Do not stop Wegovy without seeking medical advice, as your clinician needs to assess your overall treatment plan and ensure appropriate follow-up. They may recommend continuing at a lower dose, switching to an alternative weight management approach, or providing additional support to manage side effects whilst continuing treatment. In line with the UK SmPC, your clinician may consider pausing or stopping treatment if significant mood symptoms emerge. NICE guidance emphasises that weight management should be individualised, and decisions about continuing or discontinuing Wegovy should be made collaboratively between patient and healthcare professional, considering both the benefits achieved and any adverse effects experienced. Regular monitoring appointments provide opportunities to discuss any concerns about emotional wellbeing and ensure that your treatment remains safe and appropriate for your individual circumstances.

Frequently Asked Questions